Denosumab Lowers Bone Metastasis Risk in CRPC Patients - Renal and Urology News
Links shared publicly online about this topic.
- 188total visits
Denosumab Lowers Bone Metastasis Risk in CRPC Patients - Renal and Urology News
MONTREAL—Denosumab significantly prolongs bone metastasis-free survival (BMFS) and delays time to bone metastasis in men with castration-resistant prostate cancer (CRPC), according to data presented at the Canadian Urological Association annual meeting.
View full resource at renalandurologynews.com
Tags: Bone Cancer, Bone Metastasis, Bone, Osteoporosis Medication, Kidney Health, Urinary System, Prolia, Urology
Most Recently Shared on June 27, 2011 at 12:43 pm By:
Denosumab Lowers Bone Metastasis Risk in CRPC Patients: MONTREAL—Denosumab significantly prolongs bone metastasi... http://bit.ly/kirhJQ
Advertisement
